Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease.
The effect of TTC-909 (isocarbacyclin methyl ester (CAS 88931-51-5, TEI-9090) incorporated into lipid microspheres) on obstruction of the peripheral artery was studied in two different animal models. The first was a peripheral occlusion model induced by intra-arterial injection of sodium laurate in rats. The second was a tail gangrene model induced by subcutaneous injection of both ergotamine and epinephrine in rats. Intravenous bolus-administered TTC-909 at 1.0 microgram/kg resulted in the inhibition of both progression of lesions induced by sodium laurate and the extension of tail gangrene by ergotamine and epinephrine. Moreover, the inhibitory effect of TTC-909 was more potent than that of PGE1 (LM) (prostaglandin E1 incorporated into lipid microspheres). These findings suggested that TTC-909 may be clinically useful for the therapy of peripheral vascular disorders such as thromboangiitis obliterans (TAO) and atherosclerosis obliterans (ASO).
D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D004337:Drug Carriers; D004837:Epinephrine; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004878:Ergotamine; D005734:Gangrene / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D007850:Lauric Acids; D008081:Liposomes; D008297:Male; D016491:Peripheral Vascular Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013623:Tail / Q000473:pathology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D004337:Drug Carriers; D007850:Lauric Acids; D008081:Liposomes; C068518:TTC 909; D014665:Vasodilator Agents; D011464:Epoprostenol; D000527:Alprostadil; D004878:Ergotamine; D004837:Epinephrine